The role of Frailty on Adverse Outcomes Among Older Patients with COVID-19고령 COVID-19 환자의 역효과에 대한 노쇠의 역할Article Published on 2020-12-012022-09-11 Journal: The Journal of Infection [Category] SARS, 치료기술, [키워드] 95% CI adjusted odds ratio adjusted odds ratios Adverse adverse outcome adverse outcomes characterized clinician cohort study conducted COVID-19 COVID-19 patient defined discharged effective frailty group health systems Healthcare provider healthcare providers highest hospital Hospitalized hospitalized patient in-hospital mortality in-hospital mortality rate in-hospital mortality rates infected with COVID-19 management mortality rates Observed older population Patient Primary outcome provide risk therapeutic Turkey were excluded with COVID-19 [DOI] 10.1016/j.jinf.2020.09.029 PMC 바로가기 [Article Type] Article
Characterisation of 22445 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort studyObservational Study Published on 2020-11-252022-10-04 Journal: PLoS ONE [Category] MERS, SARS, 임상, [키워드] Admission adverse outcome age approach Asian black children cohort study collected Comorbidity COVID-19 COVID-19 infection COVID-19 test death discharged female greater hospital initial ISRCTN less Lung disease male management median median age men men and women much lower NEWS2 Observational cohort study organ support Patient patient group performance status positive COVID-19 presenting rates of admission Registration renal retrospective Sex subgroup United Kingdom white worse prognosis [DOI] 10.1371/journal.pone.0240206 PMC 바로가기 [Article Type] Observational Study
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patientsCOVID-19 환자를 치료하기 위해 HCV 프로테아제 억제제 다노프레비르를 사용한 첫 번째 임상 연구Clinical Trial Published on 2020-11-252022-09-11 Journal: Medicine [Category] SARS, 신약개발, 임상, 치료제, [키워드] adverse outcome approved approved drug approved drugs China chronic hepatitis clinical study coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CT scan CT scans Danoprevir discharged Effect Efficacy enrolled evaluated HCV Hepatitis hepatitis C hepatitis C virus hospital inhibitor median naïve occurred Open-label outbreak Patient patients per day primary endpoint protease Protease inhibitor Real-time PCR Ritonavir RT-PCR Safe therapeutic option therapeutic options treat Treatment [DOI] 10.1097/MD.0000000000023357 PMC 바로가기 [Article Type] Clinical Trial
ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk FactorsArticle Published on 2020-11-212022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] ACE-2 ACE2 ACE2 expression acute respiratory syndrome adverse outcome affected AGT Algorithm Alzheimer’s disease amyloid Analysis analyzed angiotensinogen app approach Beta CALM1 calmodulin cardiovascular cardiovascular disease cardiovascular risk factors cardiovascular systems catalase CAV1 CCL2 changes in co-expression Complete component confidence level congestive heart failure coronavirus coronavirus disease COVID-19 COVID19 CVD datasets described Diagnosis disease Diseases DPP4 EGFR enrichment enrichment analysis expression data Factor Fibronectin FN1 framework functional Gene Expression groups heart tissue HSP90AA1 hypertensive identify Importance Infection information Interaction investigated lung MAST2 microRNA miR miRNA nervous system network non-insulin-dependent diabete obesity outcome Patient peptidase performed predicted prediction Protein protein-protein interaction provide regulate relative responsible risk SARS-CoV-2 SARS-COV-2 infection Signaling signaling pathway Symptoms TFRC therapeutic target tissue expression TP53 was performed [DOI] 10.3390/jcm9113743 PMC 바로가기 [Article Type] Article
The dark side of the spoon – glucose, ketones and COVID-19: a possible role for ketogenic diet?Review Published on 2020-11-202022-10-30 Journal: Journal of Translational Medicine [Category] COVID-19, SARS, [키워드] adverse outcome Anti-inflammatory Cardiovascular function Clinical outcome Clinical use Comorbidity complications COVID-19 COVID-19 disease Critical diabetes Effect effective Effects Fat mass Glucose health condition health-care system hyperglycaemia hypertension Immunity immunomodulating increase in Infection Inflammation ketogenic lean mass Metabolic rehabilitation novel coronavirus disease nutritional status obesity physiological plasma Prevent public health reduction risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection type 2 diabete VLCKD [DOI] 10.1186/s12967-020-02600-9 PMC 바로가기 [Article Type] Review
Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection중증 급성 호흡기 증후군 코로나바이러스 2 감염 유무에 관계없이 여성의 임신 결과Research Published on 2020-11-192022-09-12 Journal: JAMA Network Open [Category] SARS, 진단, [키워드] 95% CI Abnormalities abnormality acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse outcome adverse outcomes age Analysis Asymptomatic black blinded body mass body mass index Care Clinical management Cohort cohort study Composite conducted coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 Critical described diabete diabetes Disease progression disease severity during pregnancy emergency department evaluate exposure Features fetal fetal heart rate finding Frequency gestation Health Health care Health care system heart rate Hispanic hospital Hospital admission Hospitalization hospitalizations Hospitalized Illness severity Importance indication Infant Infants Infection initial Maternal maternity hospital measure Mild Neonatal Neonatal infection no difference no differences nonpregnant objective Observational cohort study occur occurred outcome outcomes parity participant pathologic pathologist pathology placental Point positive preeclampsia Pregnancy pregnant women prenatal Preterm birth Primary outcome Relative risk Relevance respiratory Result risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 positivity SARS-CoV-2 testing SARS-CoV-2–positive setting severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe or critical illness symptomatic System tested Transmission white widespread women [DOI] 10.1001/jamanetworkopen.2020.29256 PMC 바로가기 [Article Type] Research
Computed tomography characterization and outcome evaluation of COVID-19 pneumonia complicated by venous thromboembolismResearch Article Published on 2020-11-192022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] adverse outcome affected age analyzed assigned Blood BNP C-reactive protein calculated Care Characteristics Chest CT Cohort Comorbidities conducted consecutive patient correlated COVID-19 CT finding D-dimer death described detect Diagnosis discharge disease ECMO elevated evaluated Evidence extracorporeal membrane oxygenation fibrinogen Follow-up Gender higher risk ICU incidence include intensive care interleukin-6 Laboratory lactate dehydrogenase LDH logistic regression model low-dose majority material mechanical ventilation N-terminal NT-proBNP outcome Patient patients performed Pneumonia positive pro-B-type natriuretic peptide pulmonary angiography Result Retrospective study RT-PCR significantly statistical analysis statistically significant symptom onset Symptoms tertiary care hospital threshold thrombosis tomography transfer Treatment troponine two group Two patient Univariate analysis Venous Thromboembolism VTE was performed [DOI] 10.1371/journal.pone.0242475 PMC 바로가기 [Article Type] Research Article
Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry혈전-염증 활성화의 상승된 마커는 심혈관 동반 질환 및 COVID-19 질병이 있는 환자의 결과를 예측합니다: LEOSS 레지스트리의 통찰력Original Paper Published on 2020-11-192022-09-11 Journal: Clinical Research in Cardiology [Category] 바이오마커, [키워드] 95% CI Abstract Activation adverse outcome adverse outcomes Analysis analyzed Anti-inflammatory therapy anticoagulation calculated cardiovascular comorbidities cardiovascular comorbidity cardiovascular disease clinical Clinical course Clinical data Clinical stage Coagulation collected COVID-19 COVID-19 disease COVID-19 in patient CRP elevated enrolled European IL-6 IMPROVE Infection Inflammation Laboratory marker Mortality Multivariate analysis multivariate regression analysis myocardial injury open outcome Patient patients with COVID-19 patients with SARS-CoV-2 predict predictor regression analysis SARS-COV-2 infection SARS-CoV‑2 significantly higher specific biomarker specific biomarkers starting supplementary material survey the disease troponin [DOI] 10.1007/s00392-020-01769-9 PMC 바로가기 [Article Type] Original Paper
Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19COVID-19로 입원한 환자의 이전 심부전의 예후 영향Article Published on 2020-11-172022-09-11 Journal: Journal of the American College of Cardiology [Category] Coronavirus, 변종, 유전자 메커니즘, [키워드] 95% confidence interval adjusted adjusted odds ratio adverse outcome adverse outcomes age aldosterone angiotensin Characteristics classification clinical Clinical characteristics conducted coronavirus coronavirus disease coronavirus disease-2019 COVID-19 described Ejection fraction Electronic health records etiology failure functional heart heart failure higher risk history hospital Hospitalized Impact in-hospital mortality increased risk inhibitor intensive care intensive care unit left ventricular ejection fraction LVEF mechanical ventilation Mortality Mount Sinai New York City Odds ratio outcome Patient patients hospitalized Renin renin-angiotensin-aldosterone system renin-angiotensin-aldosterone system inhibitor. Retrospective analysis revision System ventricular ventricular ejection with COVID-19 women [DOI] 10.1016/j.jacc.2020.09.549 PMC 바로가기 [Article Type] Article
Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 InfectionPerspective Published on 2020-11-162022-10-31 Journal: Cancers [Category] COVID-19, [키워드] adverse outcome anti-cancer treatment cancer patient clinicians and researcher Consequences coronavirus Course COVID-19 COVID-19 patients cytotoxic T lymphocyte antigen-4 evaluate the effect Evidence exacerbated Hematological malignancies Immune checkpoint inhibitor Immune checkpoint inhibitors immune response immunosuppressive therapies increased risk Infection infection with SARS-CoV-2 information knowledge less management morbidity and mortality Mortality pandemic Patient patients with COVID-19 programmed cell death protein promote receiving risk SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection Severe infection Side effect simple solid cancer T cell Topic treated Treatment turn viral infection with COVID-19 [DOI] 10.3390/cancers12113383 PMC 바로가기 [Article Type] Perspective